エピソード

  • Special Edition: Lp(a) & CV Risk
    2026/07/24

    Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates, Dr. Neil Skolnik explores our growing understanding of this cholesterol-carrying lipoprotein.

    This special episode is sponsored with support from Lilly.

    Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

    EPISODE NOTES

    Special Edition: Special Edition: Lp(a) & CV Risk

    In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Michael Wilkinson, who goes over the history of Lp(a), the current guidelines, and the importance of screening.

    This special episode is sponsored with support from Lilly.

    Presented by:

    -Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

    -Michael Wilkinson, MD, Associate Professor of Medicine at University of California San Diego Health, and Director of the advanced lipid treatment program at UC San Diego Health, Board of Directors of the National Lipid Association and Associate editor of the American Journal of Preventive Cardiology

    References:

    -The American Heart Association PREVENT Online Calculator

    -Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects – Circulation 2025; 151:400-415

    -2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation Volume 153, Issue 17, 28 April 2026; Pages e1154-e1276

    続きを読む 一部表示
    34 分
  • Special Edition: Highlights from the ADA's 2026 Scientific Sessions
    2026/07/30

    In this special crossover episode, recorded live at the American Diabetes Association's Scientific Sessions in New Orleans, the hosts of the ADA's professional podcasts—DOC Updates, Diabetes Care "On Air", DiabetesBio, and The Points of CARE—come together to discuss key highlights and groundbreaking research presented at the 2026 meeting.

    They share expert insights across the bench-to-bedside spectrum, including basic science, clinical research, and the latest in diabetes care and education. Tune in for thoughtful reflections on what this year's findings mean for clinical practice and future research.

    Available now across all ADA professional podcast channels.

    Featured Podcasts:

    • DOC Updates – ADA's podcast for primary care

    • Diabetes Care "On Air" – From ADA's clinical research journal, Diabetes Care

    • DiabetesBio – From ADA's flagship research journal, Diabetes

    • The Points of CARE - The official podcast of Diabetes, Obesity, and CardioMetabolic CARE

    Join the Discussion with:

    • Alice Cheng, MD – Co-host of Diabetes Care "On Air"

    • Kirk Habegger, PhD – Co-host of DiabetesBio

    • Michael Rickels, MD, MS – Co-host of Diabetes Care "On Air"

    • Neil Skolnik, MD – Co-host of DOC Updates and Diabetes Day by Day

    • Kevin Williams, PhD – Co-host of DiabetesBio

    • Richard Beaser, MD – Co-host of The Points of CARE

    🔗 Learn more about ADA's full podcast portfolio:
    https://diabetesjournals.org/journals/pages/podcasts

    Subscribe to DOC Updates, Diabetes Care "On Air", DiabetesBio, and The Points of CARE on Apple Podcasts, Amazon Music, Spotify, or your preferred platform.

    続きを読む 一部表示
    45 分
  • Special Edition: Hypertension Part I—Overview and Management
    2026/08/06

    In the first episode of this special three-part series, Neil Skolnik speaks with Dr. Minesh Rajpal. Together, they provide an overview, discussing the assessment and management of high blood pressure.

    This special episode is sponsored with support from AstraZeneca.

    Presented by:

    Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

    Minesh Rajpal, MD, Attending Nephrologist and Hypertension Specialist at the Southwest Kidney Institute

    References:

    2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10)

    Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957

    続きを読む 一部表示
    34 分
  • Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!
    2026/08/10

    With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts.

    1:15 Our hosts speak with Katherine R. Tuttle, MD, FASN, FACP, FNKF, Executive Director of Research at Providence Inland Northwest Health and a Professor of Medicine at the University of Washington School of Medicine. She is an author of the article "SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis," available at doi.org/10.2337/doci26-0001.

    8:50 Next, Richard introduces Alexander Turchin, MD, MS, Director of Informatics Research at the Division of Endocrinology at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. He is an author of "Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022," available for free at doi.org/10.2337/doc26-0027.

    17:05 Richard and Jane highlight special material available in the latest issue of Diabetes, Obesity, and CardioMetabolic CARE.

    • "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026," available for free at doi.org/10.2337/doci26-0003

    • "Employment and Diabetes: A Statement of the American Diabetes Association," available for free at doi.org/10.2337/doc25-0092.

    23:40 Finally, Richard and Jane highlight some of their favorite articles from the July-August issue.

    • Vidovic, et al. Behavior Modifications From CUT-DM, Including Lifestyle Modification and Self-Efficacy doi.org/10.2337/doc25-0093

    • Chan, et al. Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes doi.org/10.2337/doc26-0019

    • Bannuru, et al. RAAS Inhibitors for the Primary Prevention of CKD in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-analysis doi.org/10.2337/doci25-0014

    • Dimentstein, et al. Goals of Care Among Caregivers of Youths With Type 1 Diabetes doi.org/10.2337/doc26-0035

    To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

    続きを読む 一部表示
    36 分
  • Efficacy and safety of CagriSema & Retatrutide, CGM benefits beyond T2D, & more!
    2026/06/30

    Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

    This month on DOC Updates:

    • Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9

    • Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0

    • Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026

    • Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7

    • Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492

    Presented by:

    • Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

    • John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

    For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

    続きを読む 一部表示
    35 分
  • Special Edition: What's Next—Once-Weekly Insulins—Mechanisms and Practical Considerations
    2026/07/17

    Continuing his exploration of once-weekly insulins, Neil Skolnik speaks with Aaron King, MD. Together, they cover the mechanisms, practical considerations, and the myriad benefits that this new therapy can have over daily basal insulin.

    This special episode is sponsored with support from Novo.

    Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

    Presented by:

    Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

    Aaron King, MD. Trained in the United States Navy in Family Medicine and certified by the American College of Diabetology, Dr. King practices outpatient diabetes management in San Antonio, Texas.

    Selected references:

    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med 2023;389:297-308

    Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. N Engl J Med 2025;393:325-335

    続きを読む 一部表示
    26 分
  • Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!
    2026/08/10

    Welcome to the latest episode (August 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

    This month on DOC Updates:

    Hirsh Elhence, Jennifer L. Dodge, Stephen Fuest, et al. National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study. Ann Intern Med. [Epub 2 June 2026]. doi:10.7326/ANNALS-25-05287

    Eva Johnsen, et al. Achieving at Least 15% Weight Loss Within 2 Years of Type 2 Diabetes Diagnosis Is Associated With Lower Risks of Macrovascular and Microvascular Complications: A U.K. Cohort Study. Diabetes Care 20 July 2026; 49 (8): 1480–1489. doi.org/10.2337/dc26-0937

    Carel W. le Roux, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England Journal of Medicine June 2026 DOI: 10.1056/NEJMoa2600751

    Yu Wang, Shichao Tang, Xilin Zhou, Ping Zhang. National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000–2022. Diabetes Care 20 July 2026; 49 (8): 1414–1419. https://doi.org/10.2337/dc25-2040

    Jelle M. Beernink, et al. Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial. Diabetes Care 20 July 2026; 49 (8): 1434–1441. https://doi.org/10.2337/dc26-0882

    Welch M, Forst T, Jia W et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. The Lancet, 2026; 408, 125-140 DOI: 10.1016/S0140-6736(26)00800-7

    Presented by:

    Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

    John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

    DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice.

    For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

    続きを読む 一部表示
    32 分
  • Special Edition: Medications in the Pipeline for Cardiometabolic Disease
    2026/06/25

    In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Juan Frias, who catalogues the latest cardiometabolic medications, emphasizing the distinguishing characteristics of each.

    This special episode is sponsored with support from Lilly.

    Presented by:

    Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

    Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science

    続きを読む 一部表示
    25 分